OTHER INFORMATION
−Removed: None of our directors or officers have adopted , modified , or terminated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the nine months ended September 30, 2025.
+Added: None of our directors or officers have adopted , modified , or terminated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the three months ended March 31, 2026.
The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Quarterly Report.
2 unchanged sentences
(incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on September 22, 2025).
+Added: Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on April 16, 2026).
+Added: Form of Series H Common Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed on April 16, 2026).
+Added: Form of Securities Purchase Agreement, dated as of April 15, 2026 by and among Acurx Pharmaceuticals, Inc.
+Added: and the purchasers party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on April 16, 2026).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
Acurx Pharmaceuticals, Inc.
−Removed: November 12, 2025
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 12, 2025
/s/ Robert G.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.